Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? a matched case-control propensity-adjusted study

Clinical Infectious Diseases

Volumn 60, Issue 2, 2015, Pages 216-222

  Kalil, Andre C ^a   Syed, Ather ^b   Rupp, Mark E ^a   Chambers, Heather ^a   Vargas, Luciano ^b   Maskin, Alexander ^b   Miles, Clifford D ^c   Langnas, Alan ^b   Florescu, Diana F ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Infectious Diseases Lakeshore Medical Group ^*  (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

mortality; sepsis; transplantation

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLOGRAFT; ARTICLE; BACTEREMIA; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAFT RECIPIENT; HOSPITAL INFECTION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL; TREATMENT OUTCOME;

BACTEREMIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84924974661     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu789     Document Type: Article

References (14)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54.
2. Kalil AC, Dakroub H, Freifeld AG. Sepsis and solid organ transplantation. Curr Drug Targets 2007; 8:533-41.
3. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33:629-40.
4. Abbott KC, Oliver JD 3rd, Hypolite I, et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am J Neph-rol 2001; 21:120-7.
5. Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin Transplant 2005; 19:230-5.
6. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13:260-8.
7. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009; 37:291-304.
8. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481-3.
9. National Healthcare Safety Network. Tracking infections in acute care hospitals/facilities. Available at: http://www.cdc.gov/nhsn/acute-care-hospital/index.html. Accessed 15 September 2014.
10. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-7.
11. Turnbull IR, Clark AT, Stromberg PE, et al. Effects of aging on the im-munopathologic response to sepsis. Crit Care Med 2009; 37:1018-23.
12. Levy MM, Artigas A, Phillips GS, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 2012; 12:919-24.
13. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-55.
14. Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309:1154-62.